A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
A phase 2 trial of Intismeran autogene, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) is a phase 2 interventional study registered as NCT07221474 by Merck Sharp & Dohme LLC, with 180 participants planned, started 2025-12-12 and due to reach its primary completion in 2029-07-02. Interventions recorded: Intismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel. Conditions listed: Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
Shares Intismeran autogene, Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Intismeran autogene, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.